When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
In October 2018, Paratek Pharmaceuticals (PRTK) received FDA approvals for its two main products - SEYSARA and NUZYRA. The company also entered into an exclusive licensing agreement with Almirall (LBTSF) for the development and commercialization rights of SEYSARA, which was launched in the United States in January 2019. The other drug, NUZYRA, was launched by Paratek in February 2019. Thus, the company is expected to start recording sales revenues from this quarter onward. However, it is noteworthy that the market for antibiotics is very competitive while having low sales growth. Hence,